See the DrugPatentWatch profile for kerendia
The retail price of Finerenone (Kerendia) is approximately $550 per month for a 30-day supply of 20 mg tablets [1]. However, the actual cost to patients can vary significantly due to insurance coverage, copay programs, and other discounts [1].
What are Kerendia's pricing options and patient assistance programs?
Patients may be able to reduce their out-of-pocket expenses through manufacturer-sponsored copay savings cards, which can offer savings of up to $250 per month for eligible commercially insured patients [1]. For individuals who are uninsured or underinsured, Bayer (the manufacturer of Kerendia) offers the Bayer Patient Assistance Foundation, which provides medication at no cost to eligible patients based on income and insurance status [1]. Additionally, prescription discount cards and coupons from various providers can offer savings, though eligibility and discount amounts vary [1].
When does Kerendia's patent protection expire?
The patent landscape for Finerenone (Kerendia) is complex, with multiple patents covering the drug and its uses. According to DrugPatentWatch.com, the earliest anticipated patent expiry date for Finerenone is in 2032, though other patents extend further into the future [2]. These later-expiring patents could affect the timeline for generic entry [2].
What is Finerenone (Kerendia) and what is it used for?
Finerenone, marketed as Kerendia, is a medication used to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal heart attack, and stroke in adults with chronic kidney disease (CKD) associated with type 2 diabetes [3]. It works by selectively blocking the mineralocorticoid receptor (MR) [3]. This mechanism helps to reduce inflammation and fibrosis in the kidneys and cardiovascular system, which are often associated with CKD and diabetes [3].
How does Kerendia compare to other CKD treatments?
Kerendia offers a novel approach to managing CKD in patients with type 2 diabetes by targeting inflammation and fibrosis, distinct from traditional treatments that focus on blood pressure or glucose control [3]. While ACE inhibitors and ARBs are standard therapies for CKD in diabetic patients, Kerendia provides an additional layer of protection for those at higher risk [3]. Clinical trials have demonstrated its efficacy in reducing kidney and cardiovascular events in this population [3].
What are the risks and side effects of Kerendia?
The most common side effects reported with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [3]. Patients taking Kerendia require regular monitoring of their potassium levels and kidney function [3]. It is contraindicated in patients with Addison disease and in those taking certain medications that can increase potassium levels [3].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/kerendia
[2] https://www.drugpatentwatch.com/drug/kerendia
[3] https://www.drugpatentwatch.com/drug/kerendia